期刊文献+

尿酸性肾病大鼠模型的建立 被引量:1

The Establishment of Rat Model with Uric Acid Nephropathy
下载PDF
导出
摘要 目的:考察4种不同的方法,建立稳定的尿酸性肾病(UAN)大鼠模型。方法:50只雄性SD大鼠随机分成5组,正常对照组实验过程中正常饲养;模型Ⅰ、Ⅱ、Ⅲ组给予10%高酵母饲料喂养,同时分别给予腺嘌呤每日50 mg/kg、100 mg/kg、200 mg/kg灌胃;模型Ⅳ组按腺嘌呤100 mg/kg、乙胺丁醇250mg/kg的比例,配置成混悬液每日350 mg/kg灌胃,连续给药21 d,制造UAN模型。实验前、实验第10天、第21天大鼠测定血清UA、BUN、CR水平;HE染色观察肾脏组织病理变化;免疫组化法观察肾脏组织尿酸盐阴离子交换器1(URAT1)、有机阴离子转运子1(OAT 1)、有机阳离子转运体2(OCT 2)的表达。结果:模型Ⅰ组UA、BUN、CR水平较正常组轻微升高(P>0.05);模型Ⅱ组UA、BUN、CR水平在第10天、第21天较正常组升高(P<0.05);模型Ⅲ、Ⅳ组仅在第10天UA水平较正常组升高(P<0.05);BUN、CR水平在第10天、第21天,较正常组升高明显(P<0.05)。HE染色病理切片结果提示:各模型组肾小管和间质均有不同程度的损伤,模型Ⅱ、Ⅲ、Ⅳ组肾组织内可见黄褐色结晶,其中模型Ⅲ、Ⅳ组肾组织存在广泛性损害。免疫组化法观察肾组织蛋白表达情况:模型Ⅱ、Ⅲ、Ⅳ组URAT 1蛋白表达较正常组上调(P<0.05,P<0.01);同时,OAT 1、OCT 2蛋白表达较正常组下调(P<0.05,P<0.01)。结论:采用酵母和腺嘌呤适合剂量联合用药,可建立稳定的UAN大鼠模型。 Objective To establish the rat model of uric acid nephropalhy(UAN). Methods Fifty SD rats were randomly divided into 5 groups: rats in control group were given normal diet; model group I , Ⅱ, Ⅲ were given 10% yeast and adenine at a dosage of 50rag- kg-1· d-1, 100mg·kg-1·d-1 and 200mg·kg-1·d-1 by gavage respectively. Then model IV was given adenine 100 mg. kg-1·d-1 and ethambutol 250 rag. kg-1·d-1 by gavage for 21 days. The levels of serum uric acid(UA), blood urea nitrogen(BUN), creatinine(CR) were respectively measured before the experiment, on the day of 10 th and 21 th. The pathological changes of renal tissue were observed by HE stainning and the expressions of Uratl, OAT 1 and OCT 2 were observed by immunohistodaemistl after their sacrifice. Results Compared with control group, the levels ofUA, BUN, CR of model group I were increased slightly (P ~ 0.05), the levels of UA, BUN, CR of model group II were increased steady on the 10th and 21th day (P 〈 0.05). The levels of UA of model group Ⅲ and model group Ⅳ were increased on 10th day (P 〈 0.05), and the levels of BUN, CR of these two groups had a statistical significance on 10th and 21th day (P 〈0.01). The results of pathological sections HE staining showed that the tubular and interstitial were injury in all 4 model groups, and there were various damgges of the renal tissue in model group Ⅲ and Ⅳ. Immunohisto- chemistry results showed that the expressions of URAT 1 in model Ⅱ, Ⅲand Ⅳ were increased (P 〈 0.05), while expression of OAT 1 and OCT2 were decreased(P〈 0.05), compared with the control group. Conclusion The rat model of uric acid nephropathy(UAN) has been successfully established with adenine and the diet of yeast.
出处 《深圳中西医结合杂志》 2013年第5期283-287,306,F0003,共7页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
基金 广东省科技计划项目(2011B080701007)
关键词 尿酸性.肾病 大鼠模型 酵母 腺嘌呤 URAT1 OAT1 OCT 2 Uric acid nephropathy Rat model Yeast Adenine URAT1 OAT1 OCT2
  • 相关文献

参考文献10

  • 1奚九一,赵兆琳,鲁培基,屈立志,王义成.高尿酸血症肾病的实验动物模型研究[J].上海中医药杂志,2001,35(10):10-12. 被引量:53
  • 2熊湘明,曲竹秋.大鼠高尿酸血症模型建立[J].天津中医学院学报,2001,20(4):28-29. 被引量:83
  • 3Wu X, Wakamiya M, Vaishnav S, et al. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice [J]. Proc Natl Acad SciUSA, 1994, 91(2):742-746.
  • 4周小舟,张盛光,阳晓,魏毅.腺嘌呤所致大鼠慢性肾功能衰竭的机理研究[J].基础医学与临床,1997,17(1):54-57. 被引量:76
  • 5Enomoto A,Kimura H,ChairoungduaA, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels [J]. Nature, 2002, 417(6887): 447-452.
  • 6孙红,王少明,庄捷,黄旭慧,姚锦州.土茯苓等中药抑制URAT1表达及降尿酸作用筛选研究[J].中国临床药理学与治疗学,2012,17(4):403-407. 被引量:72
  • 7Hosoyamada M, Sekine T, Kanai Y, et al. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney [J]. Am J Physiol, 1999, 276(1 Pt 2):F122-128.
  • 8Hua J, Huang P, Zhu CM, et al. Anti-hyperuricemic and nephroprotective effects of Modified Simiao Decoction in hyperuricemic mice [J]. J Ethnopharmacol, 2012, 142(1): 248-252.
  • 9Zhang L, Dresser M J, Gray AT, et al. Cloning and functional expression of a human liver organic cation transporter [J]. Mol Pharmacol, 1997, 51(6):913-921.
  • 10Habu Y, Yano I, Okuda M, et al. Restored expression and activity of organic ion transporters rOAT1, rOAT3 and rOCT2 after hyperuricemia in the rat kidney[J]. Biochem Pharmacol, 2005, 69(6):993-999.

二级参考文献15

  • 1郑平东,朱燕俐.用腺嘌呤制作慢性肾功能衰竭动物模型[J].中华肾脏病杂志,1989,5(6):342-344. 被引量:115
  • 2张梓荣.腺嘌呤所致大鼠慢性肾功能衰竭的病理形态改变及其应用意义[J].北京实验动物科学与管理,1994,11(3):58-58.
  • 3周小舟,张盛光,阳晓,魏毅.腺嘌呤所致大鼠慢性肾功能衰竭的机理研究[J].基础医学与临床,1997,17(1):54-57. 被引量:76
  • 4Iwaki K,Yonetani Y. Hyperuricemic effects of cho- linergic agents in rats[J]. Japan J Pharmeol. 1982, 32(2) :343--349.
  • 5Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion ex- changer that regulates blood urate levels[J]. Na- ture, 2002, 417(6887): 447--452.
  • 6Enomoto A, Niwa T, Kanai Y, et al. Urate trans- porter and renal hypouricemia[J]. Rinsho Byori, 2003, 51(9) :892--897.
  • 7Kong LD, Yang C, Ge F, et al. A Chinese herbal medicine Ermiao wan reduces serum uric acid level and inhibits liver xanthin dehydrogenase and xan- thine oxidase in mice[J]. J Ethno Pharmacol,2004, 93(2/3) :325--330.
  • 8Nindita Y, Hamada T, Bahrudin U, et al. Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA [J]. Arzneimittelfors- chung, 2010, 60(4): 186--188.
  • 9Kong LD, Cai Y, Huang WW, et al. Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout[J]. J Ethno Pharmacol, 2000,73 (3) :199--207.
  • 10胡明昌,国外医学泌尿系统分册,1993年,2期,71页

共引文献264

同被引文献22

  • 1应振华,丁振华.风湿Ⅱ号合剂预防原发性痛风复发的临床研究[J].浙江中西医结合杂志,2005,15(6):336-337. 被引量:5
  • 2闫卫红,赵勇,李玉峰,张宇,鲁卫星,王程,肖珉.高尿酸血症相关因素调研及其中医证候学研究[J].中华中医药杂志,2007,22(4):247-249. 被引量:26
  • 3陈灏珠,主编.实用内科学[M]第12版.北京:人民卫生出版社,2005.1 231-1 245.
  • 4中华人民共和国卫生部.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002.68-74.
  • 5陈光亮,刘海鹏,韩茹,徐叔云.萆薢总皂苷合用牛膝总皂苷降血尿酸和抗炎作用的组方合理性研究[J].中国药理学通报,2007,23(11):1467-1471. 被引量:71
  • 6Yang B, Mo Z, Wu C, et al. A genome - wide association study i- dentifies common variants influencing serum uric acidconcentrations in a Chinese population. BMC Med Genomics,2014,7( 1 ) :10.
  • 7Wu W, Yang D, Tiselius HG, et al. The Characteristics of the Stone and Urine Stone Composition in Chinese Stone Formers: Primary Re- port of a Single - center Results. Urology,2014, S0090 - 4295 ( 13 ) 01456 - 8.
  • 8Zhou J, Chen Y, Liu Y, et al. Plasma uric acid level indicates tubu- lar interstitial leisions at early stage of IgA nephropathy. BMC Neph- rol,2014,15( 1 ) :11.
  • 9Feig DI. Serum uric acid and the risk of hypertension and chronic kidney disease. Curt Opin Rheumato1,2014,26 (2) : 176 - 85.
  • 10Skak - Nielsen H, Torp - Pedersen C, Finer N, et al. Uric acid as a risk factor for cardiovascular disease and mortality in overweight/ obese individuals. PLoS One ,2013,8 ( 3 ) : e59121.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部